Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris

Adverse events were generally consistent with those seen in previous Rituxan clinical studies in PV and other approved autoimmune indications.